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Abstract
Virchow’s triad is traditionally invoked to explain pathophysiologic mechanisms leading to
thrombosis, alleging concerted roles for abnormalities in blood composition, vessel wall
components, and blood flow in the development of arterial and venous thrombosis. Given the
tissue-specific bleeding observed in hemophilia patients, it may be instructive to consider the
principles of Virchow’s triad when investigating mechanisms operant in hemostatic disorders as
well. Blood composition (the function of circulating blood cells and plasma proteins) is the most
well-studied component of the triad. For example, increased levels of plasma procoagulant
proteins such as prothrombin and fibrinogen are established risk factors for thrombosis, whereas
deficiencies in plasma factors VIII and IX result in bleeding (hemophilia A and B, respectively).
Vessel wall (cellular) components contribute adhesion molecules that recruit circulating
leukocytes and platelets to sites of vascular damage, tissue factor, which provides a procoagulant
signal of vascular breach, and a surface upon which coagulation complexes are assembled. Blood
flow is often characterized by two key variables: shear rate and shear stress. Shear rate affects
several aspects of coagulation, including transport rates of platelets and plasma proteins to and
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from the injury site, platelet activation, and the kinetics of fibrin monomer formation and
polymerization. Shear stress modulates adhesion rates of platelets and expression of adhesion
molecules and procoagulant activity on endothelial cells lining the blood vessels. That no one
abnormality in any component of Virchow’s triad fully predicts coagulopathy a priori suggests
coagulopathies are complex, multifactorial and interactive. In this review, we focus on
contributions of blood composition, vascular cells, and blood flow to hemostasis and thrombosis,
and suggests cross-talk among the three components of Virchow’s triad is necessary for
hemostasis and determines propensity for thrombosis or bleeding. Investigative models that permit
interplay among these components are necessary to understand the operant pathophysiology, and
effectively treat and prevent thrombotic and bleeding disorders.
Introduction
Abnormalities in blood coagulation are the leading cause of death world-wide, with
treatment costs estimated at more than $250 billion and projected to more than triple to
$818.1billion by 2030.1 In addition to inherited bleeding and thrombotic disorders,
therapeutic approaches to manage hemorrhagic and thrombotic episodes are expected to
paradoxically increase the incidence of thrombotic and bleeding events, respectively. For
example, while the hemostatic agent recombinant factor VIIa is highly effective at
minimizing bleeding in hemophilic patients with inhibitors, its off-label use in
nonhemophilic patients has been associated with thrombosis.2 Similarly, whereas the
recently approved antithrombotic dabigatran exhibits improved safety and efficacy
compared to warfarin, there is currently no rapid reversal agent, which may leave patients
prone to bleeds.3 Understanding mechanism(s) of blood coagulation and its associated
disorders will allow design of targeted, and therefore safer and more effective, therapeutics
to treat both bleeding and thrombosis.
Tissue factor (TF), thrombin, and fibrin(ogen) in clot formation and stability
Procoagulant activities have been traditionally separated into extrinsic, intrinsic, and
common pathways; however, the acknowledgement that thrombin generation must be
localized to a site of injury, as well as complex presentation of certain factor deficiencies,
has led to the conceptual integration of these pathways.4 Briefly, coagulation is initiated via
extrinsic activity after exposure of cell-derived TF, formation of the factor VIIa/TF
complex, and conversion of factor X to factor Xa. Thrombin generation is subsequently
augmented by intrinsic (factors XI, IX, and VIII-dependent) activities. Though both the
extrinsic (factor VIIa/TF) and intrinsic (factors IXa/VIIIa) tenase complexes produce factor
Xa, the relative contributions of these activities are dictated, in part, by the local TF
concentration and type of cell surface supporting enzyme/cofactor complex assembly
(discussed below). Cellular and plasma-dependent mechanisms culminate in prothrombinase
complex (factors Xa, Va, and prothrombin) assembly, and production of the enzyme
thrombin. Most current antithrombotic agents target one or more of the active enzymes
generated during the clotting cascade, including factors Xa, IXa, and thrombin.
Proteolytic conversion of circulating, soluble fibrinogen to an insoluble fibrin meshwork
involves thrombin-mediated cleavage of N-terminal peptides from fibrinogen, end-to-end
polymerization of fibrin monomers to protofibrils, and lateral aggregation of protofibrils to
fibers. This sequence of events has been extensively studied and reviewed.5–7 Fibrin’s
remarkable biophysical characteristics make it extraordinarily suited to provide structural
support to the clot; individual fibers can be strained more than 330% without rupturing.8 As
such, fibrin is an effective therapeutic target for both minimizing bleeding in hemostatic
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disorders9, and dissolving intravascular thrombi in myocardial infarction, ischemic stroke,
and deep vein thrombosis.10–12
Determinants of fibrin network characteristics have been almost entirely studied in purified
systems or in platelet-poor plasma. These studies have shown that the conditions under
which fibrinogen is converted to fibrin determine the fiber thickness, branching, and
network density of the resulting clot. These conditions include the local pH, ionic strength,
and concentrations of calcium, polyphosphate, fibrin(ogen)-binding proteins (e.g. factor
XIII), thrombin, and fibrinogen present during fibrin formation.13–19 Of these, the influences
of thrombin, fibrinogen and factor XIII on fibrin structure and function have been the best
characterized. At a constant fibrinogen concentration, low thrombin concentrations produce
coarse, unbranched networks of thick fibrin fibers, whereas high thrombin concentrations
produce dense, highly branched networks of thin fibers.15,16 Similarly, at a constant
thrombin concentration, increasing the fibrinogen concentration produces denser, highly-
branched fibrin networks.16–18 The structural composition of a fibrin clot is important
because the structure determines its biochemical and mechanical properties (reviewed in 20).
In general, coarse networks have a lower elastic modulus (ability to undergo elastic
deformation, “stress/strain”) and increased susceptibility to fibrinolysis, whereas dense
networks have a higher elastic modulus and are relatively resistant to fibrinolysis.18,21,22
Factor XIII activity provides additional mechanical and biochemical support for the fibrin
network by cross-linking adjacent chains, as well as inhibitors (α2-antiplasmin) to the
clot.19,23
Pathophysiologic mechanisms in thrombosis and bleeding
Although the origin is highly controversial24, the concept of concerted pathogenic roles for
the triad of abnormalities in blood composition, vessel wall function, and blood flow/shear
in venous thrombosis/thromboembolism is typically attributed to Rudolph Virchow in the
1700s.25 Regardless of its controversial origins, the conceptual integration of these functions
has considerably advanced understanding of the pathogenesis of thrombosis as well as
bleeding (Figure 1). Specific components of Virchow’s triad are illustrated in Figure 2.
Abnormal levels of pro- and anticoagulant proteins26–44, thrombin generation39–45, clotting
factor activity46 or resistance to inactivation47,48, markers of vascular cell damage or
activation49,50, and fibrinolysis inhibitors51,52, have been correlated with venous and/or
arterial coagulopathies in case reports and small and large epidemiologic studies. That no
one abnormality predicts coagulopathy a priori highlights the complex, interconnected
pathways in which these components regulate coagulation.
Arterial thrombosis is typically associated with atherosclerotic plaque rupture. This
pathogenic process results in exposure or release of subendothelial cells and procoagulant
material (e.g., TF, collagen) from within the plaque and activation and aggregation of
platelets. The growing thrombus increases the degree of stenosis which can result in
extremely high shear rates (up to 70,000 s−1) within the stenotic region.53 In some cases,
depending on stenosis geometry and location in the vasculature, turbulent flow may develop
downstream of the stenosis. Ultimately, platelet accumulation and fibrin deposition produces
an occlusive platelet-rich intravascular thrombus (Figure 3).
In contrast, venous thrombosis/thromboembolism is typically associated with plasma
hypercoagulability and thought to be triggered by expression of procoagulant activity on
intact endothelium from inflammation and/or stasis/reduced blood flow resulting from
prolonged immobility. Venous clots have regions or layers showing substantial erythrocyte
incorporation (Figure 4).
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Given the tissue-specific bleeding (predominantly joints and muscles) observed in
hemophilia patients54–56, it may also be instructive to consider the principles of Virchow’s
triad when interrogating mechanisms operant in hemostatic disorders. Hemostasis is the
response to bleeding resulting from transection of the full thickness of the vessel wall and
extravasation of blood into the extravascular space. Hemophiliacs rarely bleed into tissues
with high subendothelial/extravascular TF expression, suggesting relative contributions from
blood composition (levels of circulating coagulation factors) and tissue-specific coagulant
activity (e.g., local TF or thrombomodulin expression) dictate hemostatic potential at an
injury site.
Predicting thrombotic or hemorrhagic events and devising targeted approaches for
minimizing these events requires thorough consideration of mechanisms that promote these
pathologies. This review focuses on the procoagulant contributions of blood composition,
vasculature, and flow/shear to hemostasis and thrombosis.
Contributions of plasma procoagulant activity in thrombosis and bleeding
Likely due to the ease of obtaining blood for ex vivo experiments, blood composition
(circulating blood cells and plasma proteins) is the best-characterized facet of Virchow’s
triad. Techniques to evaluate the isolated effects of abnormal plasma clotting factor levels in
purified assays have given way to technologies that measure the global hemostatic potential
of blood and plasma. These newer techniques permit translation of changes in individual
factor levels to net changes in thrombin generation and clot formation and stability.
Deficiencies in either factor VIII or IX (hemophilia A or B, respectively) are well-
characterized hypocoagulabilities in which patients produce a primary platelet plug in
response to vascular injury, but typically re-bleed hours to days after injury. In vitro studies
show hemophilic conditions result in reduced thrombin generation, with a prolonged onset
and lower thrombin generation rate and peak level.39,41–43 This abnormal thrombin
generation pattern causes deficiencies in fibrin production, fibrin network density and
permeability, and susceptibility of the fibrin network to fibrinolysis.38–42,57–59 Both
replacement and bypassing strategies used to treat and prevent bleeding in hemophilia
improve thrombin generation variables and accelerate and stabilize the resulting fibrin
network.40,42,58,60
The role(s) of elevated plasma factor levels (hypercoagulabilities) on clotting are less well
understood. Elevated prothrombin levels, typically associated with a glycine to arginine
mutation at residue 20210 (G20210A), increase risk of venous thrombosis.26 The
mechanism for this correlation is currently unclear. Patients with the G20210A mutation do
not have elevated levels of the prothrombin cleavage product fragment 1.2, suggesting
coagulation is not activated at baseline.61 However, in vitro assays with reconstituted
systems and patient plasma suggest once coagulation is triggered, hyperprothrombinemia
increases the rate and peak of thrombin generation.61–65 This apparent paradox may be
reconciled by the hypothesis that low levels of thrombin activation are functionally
anticoagulant because thrombin in complex with thrombomodulin activates negative
feedback pathways to limit coagulation, whereas the in vitro assays are triggered with higher
TF concentrations that overwhelm anticoagulant mechanisms and promote higher
procoagulant activity. In the in vitro assays, increased thrombin generation results in the
formation of fibrin clots composed of a fine network of thin fibrin fibers63 and increased
activation of the thrombin-activable fibrinolysis inhibitor (TAFI)66, mechanisms that have
both been correlated with increased thrombosis risk. Thus, although still to be demonstrated
in vivo, these data suggest a mechanism correlating elevated prothrombin, thrombin
generation, and clot stability.
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Abnormalities in fibrin(ogen) synthesis, formation and function are implicated in both
bleeding and thrombotic disorders. More than 500 fibrinogen gene mutations have been
identified that result in expression of low (afibrinogenemia) or abnormally functioning
(dysfibrinogenemia) fibrinogen chains. In addition, posttranslational modification (e.g.,
oxidation, nitration, homocysteinylation, and glycation) of circulating fibrinogen has been
implicated as an “acquired dysfibrinogenemia” in prothrombotic disorders, including acute
coronary syndrome, diabetes, hyperhomocysteinemia, and thrombosis associated with acute
cigarette smoke exposure, presumably because it alters fibrinogen cleavage, incorporation of
fibrin into the fibrin network, and/or fibrin network stability67. Although an elevated
fibrinogen level (hyperfibrinogenemia) is a well-established risk factor for both arterial and
venous thrombosis29–35,49,68, its etiologic role has been controversial. Transgenic mice that
over-express murine fibrinogen show elevated fibrin degradation products (D-dimer) and
spontaneous fibrin deposition in the spleen, but only marginal shortening of the time to 75%
occlusion after 20% ferric chloride (FeCl3) application to the carotid artery.69–71 Using a
different hyperfibrinogenemia model in which wild type mice were infused with human
fibrinogen, we showed that hyperfibrinogenemia shortens the time to occlusion after
application of 10% and 5% FeCl3 to the carotid artery and saphenous vein, respectively.18
Furthermore, hyperfibrinogenemia increases thrombus fibrin content, promotes faster fibrin
formation, and increases fibrin network density, strength, and stability. Importantly,
hyperfibrinogenemia increases resistance to pharmacologically induced thrombolysis in
vivo. These data demonstrate a direct, etiologic link between hyperfibrinogenemia,
thrombosis, and thrombolysis in acute settings.18
Contributions of cellular procoagulant activity in thrombosis and bleeding
Vascular cells contribute at least two essential functions during coagulation. First, cellular
adhesion molecules including P-selectin glycoprotein ligand-1 (PSGL-1) exposed during
vascular injury recruit leukocytes and platelets to sites of vascular damage72. Second,
accumulation of these cells, as well as exposure of active cellular TF (normally sequestered
from blood in healthy humans) provides a procoagulant signal of vascular breach and a
surface upon which to assemble procoagulant complexes. Evidence suggests extravascular
TF exists in complex with factor VIIa73, such that vascular injury exposes the fully formed
factor VIIa/TF complex, enabling immediate activation of factor X to factor Xa. Subsequent
assembly of the prothrombinase complex (factors Xa, Va, and prothrombin) takes place on
the negatively charged lipid (phosphatidylserine) surface provided by TF-bearing cells and
activated platelets. Cells also provide a site for factor XI(a) binding and activation of factor
IX, as well as assembly of the intrinsic tenase complex (factors IXa, VIIIa, and X) to
augment thrombin generation.
We and others have directly compared the procoagulant activity of intravascular and
extravascular cells and their ability to support fibrin formation. Whereas quiescent
intravascular cells have little to no TF activity, extravascular cells (e.g., fibroblasts and
smooth muscle cells) express considerable TF and are primed to trigger coagulation upon
contact with blood. Because thrombin dictates fibrin network formation and network
properties, the highly procoagulant extravascular cells support the rapid production of a
dense fibrin network that is relatively resistant to fibrinolysis.74–76 Such networks stabilize
the primary platelet plug at a site of vascular injury. The relative ability of extravascular
cells to trigger clotting in blood escaping from a ruptured vessel can be implicated in tissue-
specific hemostasis. Vascular breach into a site of high TF activity would not require an
intact intrinsic pathway; thrombin generation could take place entirely via the TF-driven
extrinsic pathway. In contrast, vessel disruption into tissues with lower extravascular TF
expression would necessitate intrinsic pathway activity to augment thrombin generation and
promote stable fibrin formation. For example, hemophilia patients frequently bleed into
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muscles and joints. Although this presentation has been related to physical stress placed on
these tissues54–56, hemophilia patients do not typically bleed into other tissues that endure
high physical activity such as the heart. These observations suggest that attributing bleeding
solely to physical stress oversimplifies the pathology. Cardiomyocytes express high levels of
TF, which can promote substantial thrombin generation independently of intrinsic factors
VIII and IX, suggesting tissue-specific extrinsic activity can compensate for reduced
intrinsic activity. This scenario illustrates the required integration of two components of
Virchow’s triad, blood and tissues, in maintaining hemostasis.
Extravascular TF expression/activity is implicated in arterial thrombosis resulting from
atherosclerotic plaque rupture. The amount of TF found in atherosclerotic plaques in humans
is positively correlated with the thrombogenicity of the lesions after plaquerupture.77 The
importance of TF in the progression of arterial thrombosis is underscored by observations
that treatment of human plaques with TF pathway inhibitor significantly reduces adhesion of
both fibrinogen and platelets to the plaque, indicating the thrombotic potential of
atherosclerotic lesions may be decreased by inhibiting TF-dependent procoagulant
activity.78
Inappropriate expression of intravascular procoagulant activity is hypothesized to trigger
venous thromboembolism (VTE). Proinflammatory mediators including bacterial
lipopolysaccharide, and the cytokines interleukin-1β and tumor necrosis factor-alpha (TNF-
α), induce procoagulant activity (thrombin generation) in cultured endothelial cells via de
novo TF synthesis and decreased thrombomodulin expression in a time- and dose-dependent
manner.18,76,79,80 TNF-α-stimulated, cultured endothelial cells support robust fibrin
formation.76 Laser-induced injury of cultured endothelial cells has also been shown to
induce procoagulant activity and fibrin formation, although the time course of those
experiments suggests TF activity is released from intracellular stores and is not synthesized
de novo.81 In vivo, endothelial cells residing in different vascular beds (e.g., aorta versus
pulmonary microcirculation) have different phenotypes. Even within a given vessel,
endothelial cells vary in their expression of coagulation proteins. Brooks et al. elegantly
showed increased expression of thrombomodulin and endothelial cell protein C receptor,
and decreased expression of von Willebrand factor in the valve sinus relative to the
immediately adjacent vein lumen in saphenous veins harvested during cardiac bypass
surgery.82 Although these studies convincingly show vascular bed-specific expression of
anticoagulant proteins on endothelial cells, evidence for endothelial cell TF expression in
vivo remains controversial.
Vascular bed-specific function is best illustrated clinically by the specific presentations of
thrombosis in either arterial or venous circulation, but rarely both. Additionally, risk factors
strongly associated with arterial thrombosis (e.g., hypertension, diabetes mellitus, smoking,
hypercholesterolemia) only modestly increase risk of venous thrombosis/
thromboembolism83, and meta-analysis suggests history of unprovoked VTE only slightly
increases (~1.5-fold) risk of arterial cardiovascular events over long-term followup.84
Because any abnormality in the blood is present systemically, these events reflect local
abnormalities in vascular bed-specific pro- or anticoagulant activity and/or blood flow
(discussed below). Vascular bed-specific activities are further illustrated by animal models
of coagulation dysfunction that show bleeding and/or fibrin deposition in specific tissues.
For example, mice with partial TFPI deficiency and decreased thrombomodulin function
demonstrate fibrin deposition in the brain and liver, but not other tissues.85 These
observations suggest unique regulatory mechanisms are present in specific tissues.
Neither “cell” nor “plasma protein,” cell-derived microparticles express cell-specific
markers and retain procoagulant properties derived from their parent cell86,87, and can
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circulate and evade normal spatial restrictions on cellular procoagulant activity75. Although
circulating microparticles derived from leukocytes, platelets, erythrocytes, endothelial cells,
megakaryocytes, and tumors have been identified in numerous studies (Figure 5), their
precise role(s) in hemostasis and thrombosis is poorly understood. Scott syndrome patients
have a defect that impairs the translocation of phosphatidylserine from the inner to the outer
leaflet of the membrane of erythrocytes and platelets. Although the bleeding tendency of
these patients has been primarily attributed to decreased platelet procoagulant activity,
platelets from Scott syndrome patients also demonstrate defective generation of
phosphatidylserine-positive microparticles in vitro, suggesting these microparticles are
necessary for hemostasis.88,89 However, it is difficult to separate the role(s) of reduced
expression of phosphatidylserine on platelets from reduced production of
phosphatidylserine-bearing microparticles. Healthy humans have few circulating leukocyte-
derived microparticles; however, the numbers of leukocyte-derived microparticles increase
in certain diseases, including cancer90,91, diabetes92, and sickle cell disease93.
Microparticles derived directly from tumors have also been specifically associated with VTE
in cancer patients, and are thought to contribute to the thrombotic presentation.94,95
Expression of procoagulant activity on microparticles (TF and/or phosphatidylserine) has
been implicated in microparticle function in vitro and in vivo.96–99 One prospective study
demonstrated a sharp increase in microparticle TF activity immediately before venous
thrombosis in two patients91, suggesting a causative role of microparticles in the thrombotic
event. Murine studies support this observation; human monocyte-derived microparticles
promote thrombus formation100,101 and increase thrombus weight98 in intravascular
thrombosis models. Additional theories regarding the mechanistic role(s) of microparticles
in thrombosis invoke their expression of cellular adhesion molecules and ability to activate
endothelial cells102 and leukocytes.
Contributions of blood flow in thrombosis and bleeding
The effects of blood flow on clotting are perhaps the least interrogated aspect of Virchow’s
triad. Blood flow in the vascular system is typically characterized by two key variables:
shear stress and shear rate. In laminar flow (fluid that flows in concentric, parallel layers),
shear stress (τ) is the force per unit area applied between adjacent layers of fluid, and shear
rate (γ, units of inverse time) is the relative velocity gradient between adjacent layers of
fluid. For a Newtonian fluid, such as water or plasma, shear stress is the product of fluid
viscosity and shear rate. The term “shear stress” when referring to blood flow typically
means wall shear stress, which is the tangential force that the fluid imposes directly on the
endothelium. For laminar flow in a straight vessel, wall shear stress is directly proportional
to the volumetric flow rate (volume per time) and inversely proportional to the third power
of the inner vessel diameter. In much of the arterial system, blood vessels adapt their caliber
via endothelium-mediated regulation to maintain a mean wall shear stress of approximately
5–20 dynes/cm2.103,104 This maintenance is thought to be crucial to normal vascular
function, including the promotion of antiinflammatory, antithrombotic, anticoagulant,
profibrinolytic and antihypertrophic states.104,105
Under venous conditions, static or severely reduced flow (“stasis”) leads to decreased wall
shear stress. Stasis induced by immobility (hospitalization or long-haul air travel) or trauma
is associated with venous thrombosis risk, perhaps by modulating the endothelial cell
phenotype. The shear stress-responsive Krüppel-like transcription factors (KLF) have been
implicated in endothelial cell function.106–108 Shear stress upregulates KLF expression,
inducing expression of antiinflammatory and antithrombotic proteins, including
thrombomodulin; whereas, stasis- or proinflammatory cytokine-induced loss of KLF
expression leads to enhanced expression of vascular cell adhesion molecule-1 and TF.109,110
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As such, KLF is an intriguing target for novel antithrombotics aimed at combating stasis-
induced thrombosis.
Vascular endothelial cells are also subjected to pressure, a force per area that acts
perpendicularly to the vessel wall and modulates endothelial function. Hypertension
increases pressure and mechanical damage to arteries, increasing circulating levels of both
endothelial- and platelet-derived microparticles.111 Hypertension may also increase TF
exposure in vivo; application of pressure to cultured endothelial cells increases TF
activity112 and release of endothelin-1113.
Flow conditions near a vessel wall are best characterized by wall shear rate. Wall shear rate
describes how fast solutes and platelets are delivered within a short, radial distance from the
vessel wall, but also the rate at which they are carried downstream as they diffuse away from
the wall. Model systems have shown that local flow conditions strongly regulate the delivery
of both platelets to a subendothelial surface, and factor X to a wall containing the factor
VIIa/TF complex.114 Typical arterial and venous shear rates are 500–1500 s−1 and 10–100
s−1, respectively. However, the shear rate and shear stress within a stenotic region
significantly increase as the stenosis grows; shear rates may reach 70,000 s−1 to 250,000 s−1
in severely stenotic vessels.53,115 Depending on stenosis geometry and location in the
vasculature, a recirculation zone (illustrated in Figure 3) may form immediately downstream
from the stenotic region. Recirculation zones are often characterized by low shear conditions
and long residence times for materials contained within them.116 Notably, areas of disturbed
flow such as branch points and curvatures, especially where wall shear stress is low or
oscillatory, correlate with regions of atherosclerotic lesion initiation and stenosis.104,117
Shear-dependent expression of platelet P-selectin and formation of monocyte-platelet
aggregates suggest that both platelets and leukocytes are activated when they traverse
stenotic regions (estimated peak wall shear stress of 2.64 to 281.5 Pa, correlated with
stenosis severity), priming these cells for deposition on dysfunctioning or ruptured
vasculature and/or contribution to thrombotic events if they become entrapped in the
recirculation zone.116,118 Moreover, soluble agonist-independent accumulation of platelets
at a stenotic region is attributed to flow (rheology)-dependent aggregation.119 As such, flow-
dependent changes induced by the stenosis, itself, further increase the risk of thrombosis
upon plaque rupture.
The shear rate also dramatically modulates the kinetics of both fibrin monomer formation
and polymerization.120,121 At a constant, given shear rate, initiation of clotting is a function
of the size of the exposed region of TF.120 Once initiated, the shear rate dictates both influx
of procoagulant reactants including prothrombin and fibrinogen, and efflux of reaction
products including thrombin and fibrin. In in vitro assays, increasing shear from 10 to 100
s−1 depletes local fibrin monomer concentrations, limiting lateral aggregation and protofibril
extension. However, decreasing the shear rate or increasing thrombin generation at a given
shear rate increases local monomer concentrations, permitting protofibril and subsequent
fibrin fiber formation.121 Although fibrin networks formed under static (no flow) conditions
show an isotropic distribution of fibers with relatively uniform diameters, fibrin produced in
flowing blood is oriented along flow vectors121–123, with a prominent network of thick
fibers as well as fiber “aggregates” in which multiple individual fibers are coalesced into
bundles.123 Because the fibrin network’s ability to withstand both biochemical dissolution
and mechanical disruption is a function of its fiber thickness and branching20, these studies
indicate networks produced under flow would demonstrate significantly different stability
than isotropic networks formed under stasis.123 In fact, using mechanical stress to
recapitulate the effects of blood flow on fiber orientation, a recent study found that stretched
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fibrin networks are resistant to fibrinolysis124, underscoring the importance of the effects of
blood flow/shear rate on thrombus formation, structure and function.
Multiple, inter-related “hits” in thrombosis and bleeding
The proposition that multiple “hits” culminate in abnormal coagulation suggests
simultaneous consideration of soluble, cellular, and mechanical biomarkers is required to
determine clinical risk of thrombosis and bleeding. Indeed, concerted dysfunction in the
blood, vessel wall, and blood flow may increase clinical risk via additive or even synergistic
mechanisms. Two recent studies have highlighted the need to understand the extent of vessel
wall injury when interpreting thrombotic risk related to platelet and plasma protein
functions. Hechler et al.125 addressed the controversy regarding the role of GPVI-collagen
interactions in thrombosis by showing that thrombi resulting from superficial laser injury
depended on platelet GPVI but not procoagulant activity, whereas thrombosis after deeper
laser injury that both denuded the endothelium and exposed the adventitia was less
dependent on GPVI, but instead could be blocked by hirudin. We have shown that the
procoagulant/prothrombotic effects of elevated plasma factor VIII levels can be observed
after mild vascular injury (short exposure to FeCl3), but not severe injury to the carotid
artery.126 These studies demonstrate the interdependent relationship between plasma
procoagulant activity and vascular function.
Epidemiologic studies in humans support these observations. For example, the prognostic
importance of hyperfibrinogenemia appears to be independent of, but additive to,
myocardial damage (assessed by troponin-T levels) in patients with unstable coronary artery
disease.35 However, few diagnostic algorithms simultaneously consider markers of vascular
damage and plasma hypercoagulability when determining thrombosis risk. Acevedo et al.30
showed that elevated levels of both homocysteine (a trigger of endothelial damage) and
fibrinogen contributed to an increased hazard ratio (HR) of 3.29 for 3-year mortality, more
than the HR for either homocysteine (HR=2.14) or fibrinogen (HR=2.28), alone. This
observation supports the development and use of diagnostic algorithms that incorporate
multiple biomarkers that indicate not only blood composition, but also vascular function,
when determining clinical interventions and duration of anticoagulant therapy.
Clearly then, delineating the operant pathophysiologic mechanisms necessitates
understanding the substantial cross-talk and feedback pathways that connect the aspects of
Virchow’s triad. However, a significant impediment to these investigations is the difficulty
in simulating and collecting data on multiple biochemical, cellular and mechanical processes
simultaneously. Mathematical and computational modeling is being used to circumvent this
limitation. Indeed, models of coagulation kinetics have been instrumental in delineating TF
regulatory mechanisms127,128, sensitivity of this pathway to initial TF concentration129, and
threshold behavior of thrombin production and the importance of binding site density on the
reactive surface of platelets.130,131 Fewer models have incorporated the effects of flow in
coagulation, and only a subset have generated hypotheses that were subsequently tested and
validated experimentally132–134. Of note, theoretical work by Kuharsky and Fogelson130 led
to the hypothesis that platelets physically inhibit subendothelial activity. This hypothesis
was later given experimental support135 and incorporated into the biological
literature136,137.
Two models aimed to capture interplay between the biochemistry, blood cells and fluid
environment and predict clot behavior in multiple parameter regimes. Xu et al.138 developed
a computational model that invoked the cellular potts model to represent platelets in flow,
which allowed for tracking of individual discrete platelet behaviors. Coagulation
biochemistry was based on the system described by Jones and Mann128 and did not include
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surface-dependent reactions. The model predicted that red blood cell entrapment within the
growing platelet thrombus led to thrombus heterogeneity and structural instability.
Leiderman and Fogelson139 developed a model that included detailed biochemistry,
including surface-dependent reactions, chemical activation and deposition of platelets. The
model tracked platelet concentrations rather than discrete objects and treated the growing
platelet mass as a porous material. This feature allowed analysis of fluid and solute transport
within the growing mass, and showed that diffusive transport within the mass promotes its
upstream growth. Furthermore, this model showed thrombus growth was strongly influenced
by wall shear rate and the near-wall excess of platelets. Although both models substantially
advance simulation of the complex and coupled blood clotting system under flow, the
predictions made by these models remain to be tested in biological assays. Moreover, all of
these models still lack features known to affect coagulation including effects of platelet-
platelet cohesion and clot dissolution. However, improved computing power, continued
refinement of computational models and incorporation of new experimental data into the
models are expected to identify novel therapeutic targets for the treatment of thrombosis and
bleeding.
Conclusions
Understanding the interplay between the components of Virchow’s triad is necessary to
effectively diagnose and treat bleeding and thrombotic disorders. Increasing awareness of
the complexities of these presentations, along with increasingly sophisticated technologies to
analyze soluble, cellular, and physical dysfunctions in concert will shed new light on these
pathologies and identify novel therapeutic targets. With such targets, we may achieve the
long-sought, but thus far elusive, goal for coagulation treatment: safe and effective
antithrombotic and hemostatic approaches that are not complicated by bleeding or
thrombotic risks.
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Venn diagram illustrating the propensity of thrombosis and bleeding at the intersection of
abnormalities in blood composition, vessel wall function, and blood flow/shear.
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Figure 2. Schematic showing the elements of Virchow’s triad
This conceptual model describes the three components (blood flow, blood composition,
vascular function) that regulate coagulation. Abbreviations: IX, factor IX; VIII, factor VIII;
II, prothrombin; Fgn, fibrinogen; TM, thrombomodulin
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Figure 3. Interplay between abnormalities in blood components, the vasculature, and blood flow
contribute to the development of arterial thrombosis
Arterial thrombosis involves the formation of platelet-rich "white clots" that form after
rupture of atherosclerotic plaques and exposure of procoagulant material such as lipid-rich
macrophages (foam cells), collagen, tissue factor and/or endothelial breach, in a high shear
environment. Abbreviations: TM, thrombomodulin; II, prothrombin; IIa, thrombin; Fgn,
fibrinogen; TF, tissue factor
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Figure 4. Interplay between abnormalities in blood components, the vasculature, and blood flow
contribute to the development of venous thrombosis
Venous thrombosis involves the formation of fibrin-rich “red clots” that result from
exposure of procoagulant activity on intact endothelium plus plasma hypercoagulability, in
reduced or static blood flow. Venous thrombi are thought to initiate behind valve pockets,
where reduced or static flow decreases wall shear stress that normally regulates endothelial
cell phenotype. Abbreviations: TM, thrombomodulin; EPCR, endothelial protein C receptor;
II, prothrombin; IIa, thrombin; TF, tissue factor; Fgn, fibrinogen; RBC, red blood cells
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Circulating microparticles are derived from a variety of cell types including leukocytes,
platelets, megakaryocytes, red blood cells, endothelial cells, and tumors. Microparticles
(MP) carry cell-specific markers and functional properties of their parent cell.
Wolberg et al. Page 23
Anesth Analg. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
